The safety profile of fruquintinib was consistent with the understanding of the mechanism of action of VEGFR 1-3 inhibition, with hypertension, PPE syndrome, proteinuria, and hypothyroidism being previously reported effects of VEGFR, or multi-kinase inhibition.29,31-34 Patients were closely monitored in FRESCO-2 and AESIs were effectively managed with dose modifications and supportive treatments as described in the protocol. This evidence concerns the gene KDR and hypertensive disorder.